Daiichi Sankyo

Recent Job Cuts in the Biopharma Industry
Recent Job Cuts in the Biopharma Industry
BioSpace
Tocagen
Sanofi
Amneal
Daiichi Sankyo
Integra Life Sciences
Aclaris
Bayer
Novartis
Illumina
Merck
Roche Molecular Systems
Prometheus Labs
layoffs
Flag link:
Astellas maintains lead over Daiichi Sankyo with CHMP okay for Xospata
Astellas maintains lead over Daiichi Sankyo with CHMP okay for Xospata
Pharmaforum
Astellas
AML
Xospata
Europe
Daiichi Sankyo
Flag link:
Astellas' AML drug wins over CHMP — strengthening lead on Daiichi Sankyo
Astellas' AML drug wins over CHMP — strengthening lead on Daiichi Sankyo
Endpoints
Astellas
FDA
gilteritinib
Europe
AML
Daiichi Sankyo
Flag link:
Daiichi Sankyo to cut 69 opioid sales jobs
Daiichi Sankyo to cut 69 opioid sales jobs
Beckers Hospital Review
Daiichi Sankyo
opioids
layoffs
drug reps
Flag link:
Daiichi Sankyo scores landmark FDA OK for rare tumor drug — albeit with restrictions
Daiichi Sankyo scores landmark FDA OK for rare tumor drug — albeit with restrictions
Endpoints
Daiichi Sankyo
FDA
pexidartinib
Turalio
tenosynovial giant cell tumors
Flag link:
FDA declines to approve Daiichi Sankyo's blood cancer treatment
FDA declines to approve Daiichi Sankyo's blood cancer treatment
Reuters
Daiichi Sankyo
FDA
quizartinib
acute myeloid leukemia
Flag link:
5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit
5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit
Motley Fool
Vertex Pharmaceuticals
VX-445
tezacaftor/ivacaftor
AbbVie
upadacatinib
Daiichi Sankyo
trastuzumab deruxtecan
Celgene
liso-cel
Novartis
LY3298176
Flag link:
Daiichi Sankyo Denies Report That It's Selling Over-the-Counter Drug Unit
Daiichi Sankyo Denies Report That It's Selling Over-the-Counter Drug Unit
BioSpace
Daiichi Sankyo
OTC
Flag link:
Daiichi Sankyo in talks over OTC unit sale – reports
Daiichi Sankyo in talks over OTC unit sale – reports
Pharmaforum
Daiichi Sankyo
M&A
OTC
Flag link:
Daiichi Sankyo comes up way short of promised avian flu vaccine production
Daiichi Sankyo comes up way short of promised avian flu vaccine production
Fierce Pharma
Daiichi Sankyo
vaccines
Japan
avian flu
drug shortages
Flag link:
Daiichi Sankyo Takes Two Products to FDA Advisory Panel; Gets One Yes, One No
Daiichi Sankyo Takes Two Products to FDA Advisory Panel; Gets One Yes, One No
BioSpace
Daiichi Sankyo
FDA
quizartinib
acute myeloid leukemia
pexidartinib
TGCT
Flag link:
FDA questions credibility of Daiichi data ahead of AdComm
FDA questions credibility of Daiichi data ahead of AdComm
Fierce Biotech
FDA
Daiichi Sankyo
quizartinib
acute myeloid leukemia
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs
Yahoo/Benzinga
biotech
Achillion
Sesen Bio
The Medicines Company
Amgen
Daiichi Sankyo
earnings
Flag link:
AstraZeneca's share dilution gamble on Daiichi drug pays off
AstraZeneca's share dilution gamble on Daiichi drug pays off
Biopharma Dive
AstraZeneca
Daiichi Sankyo
trastuzumab deruxtecan
metastatic breast cancer
Flag link:
AZ and Daiichi to file new breast cancer drug after trial success
AZ and Daiichi to file new breast cancer drug after trial success
Pharmaforum
AstraZeneca
Daiichi Sankyo
trastuzumab deruxtecan
antibody-drug conjugate
Flag link:
Daiichi picks immuno-oncology bispecific, triggering payout to Zymeworks
Daiichi picks immuno-oncology bispecific, triggering payout to Zymeworks
Fierce Biotech
Daiichi Sankyo
immuno-oncology
Zymeworks
bispecific antibodies
Flag link:
AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal
AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal
Yahoo/Reuters
AstraZeneca
Daiichi Sankyo
breast cancer
trastuzumab deruxtecan
Flag link:
Doubling down on R&D, Daiichi makes executive changes across its U.S. research unit
Doubling down on R&D, Daiichi makes executive changes across its U.S. research unit
Fierce Biotech
R&D
Daiichi Sankyo
Flag link:
Daiichi gets speedy FDA review for rare cancer drug
Daiichi gets speedy FDA review for rare cancer drug
Pharmaforum
Daiichi Sankyo
FDA
pexidartinib
TGCT
priority review
Flag link:
Daiichi Sankyo takes option on diabetes stem cell start-up
Daiichi Sankyo takes option on diabetes stem cell start-up
Pharmaforum
Daiichi Sankyo
stem cells
Tokyo Institute of Technology
type 1 diabetes
OiDE BetaRevive
Flag link:

Pages